Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease
-
Martina Montagnana
Abstract
Cardiovascular disease is the leading cause of mortality and morbidity in Western countries. Despite its remarkable medical and social consequences, the prevalence of peripheral arterial disease (PAD) is often underestimated among atherosclerotic disorders. So far, little is known about the behavior of traditional and emerging markers of ischemic heart disease that should allow the reliable identification of PAD patients at increased risk of developing myocardial ischemia and heart failure or dysfunction. To investigate this topic, we measured cardiac troponin T (cTnT), ischemia-modified albumin (IMA) and NT-prohormone-brain natriuretic peptide (NT-proBNP)in 35 consecutive patients with clinically ascertained PAD (stage 2–4, according to Lériche-Fontaine) asymptomatic for chest pain and current heart failure, and 20 controls displaying moderate to high cardiovascular risk factors (hypertension, diabetes, hyperlipidemia), but with no clinical evidence of PAD. Although the concentrations of cTnT and IMA were not statistically increased in PAD patients, NT-pro-BNP values were substantially higher in PAD patients than in controls (62.6 vs. 7.4pmol/L, p<0.0001). Thepercentage of subjects displaying values exceeding the specific NT-proBNP diagnostic threshold (>14.8pmol/L) was also significantly different between PAD patients and controls (74% vs. 10%, p<0.001). After excluding PAD patients exceeding the 0.01ng/mL cTnT cutoff value indicative of current ischemic cardiac involvement, the median concentration of NT-proBNP remained statistically increased (28.0 vs. 5.8pmol/L, p<0.0001). Taken together, these results indicate that NT-proBNP, but not IMA, is substantially increased in PAD patients. This finding suggests that such patients, even though asymptomatic, might develop myocardial dysfunction, and thus warrant further investigation.
References
1. Jacoby DS, Mohler ER. Peripheral arterial disease. Risk factor identification and modification. In: Abela GS, editor. Peripheral vascular disease. Basic diagnostic and therapeutic approaches. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:190–7.Search in Google Scholar
2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004; 110:738–43.10.1161/01.CIR.0000137913.26087.F0Search in Google Scholar
3. Cimminiello C. PAD. Epidemiology and pathophysiology. Thromb Res 2002; 106:V295–301.10.1016/S0049-3848(01)00400-5Search in Google Scholar
4. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004; 109:733–9.10.1161/01.CIR.0000112642.63927.54Search in Google Scholar PubMed
5. Belch JJ, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, et al. Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003; 163:884–92.10.1001/archinte.163.8.884Search in Google Scholar PubMed
6. Ng LL, Loke IW, Davies JE, Geeranavar S, Khunti K, Stone MA, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 2005; 45:1043–50.10.1016/j.jacc.2004.12.058Search in Google Scholar PubMed
7. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17:1105–7.10.1096/fj.02-0796fjeSearch in Google Scholar PubMed
8. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-Terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666–75.10.1056/NEJMoa042330Search in Google Scholar PubMed
9. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003; 108:2987–92.10.1161/01.CIR.0000103681.04726.9CSearch in Google Scholar PubMed PubMed Central
10. Talwar S, Squire IB, Downie PF, Davies JE, Ng LL. Plasma N-terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart 2000; 84:421–4.10.1136/heart.84.4.421Search in Google Scholar PubMed PubMed Central
11. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acutemyocardial ischaemia induced by dynamic exercise in patients with angina pectoris. Clin Sci (Lond) 1995; 88:551–6.10.1042/cs0880551Search in Google Scholar PubMed
12. Omland T. Clinical and laboratory diagnostics of cardiovascular disease: focus on natriuretic peptides and cardiac ischemia. Scand J Clin Lab Invest Suppl 2005; 240:18–24.10.1080/00365510500236077Search in Google Scholar PubMed
13. Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise induced skeletal muscle ischemia. Clin Chem 2004; 50:1656–60.10.1373/clinchem.2004.031690Search in Google Scholar PubMed
14. Gidenne S, Ceppa F, Fontan E, Perrier F, Burnat P. Analytical performance of the Albumin Cobalt Binding (ACB) test on the Cobas MIRA Plus analyzer. Clin Chem Lab Med 2004; 42:455–61.10.1515/CCLM.2004.079Search in Google Scholar PubMed
15. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, et al. Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001; 47:464–70.10.1093/clinchem/47.3.464Search in Google Scholar
16. McCord J. Oxygen-derived free radicals in post ischemic tissue injury. N Engl J Med 1985; 312:159–63.10.1056/NEJM198501173120305Search in Google Scholar PubMed
17. Cobbe SM, Poole-Wilson PA. The time of onset and severity of acidosis in the myocardial ischemia. J Mol Cell Biol 1980; 12:745–60.Search in Google Scholar
18. Anwaruddin S, Jannuzzi JL, Baggish AL, Lewandrowski L, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005; 123:140–45.10.1309/4BCTG5UCYMQFWBLRSearch in Google Scholar
19. Salvagno GL, Lippi G, Montagnana M, Schena F, Ballestrieri F, Guidi GC. Influence of physical exercise on the preanalytical variability of pro-BNP and IMA. Clin Chem Lab Med 2005; 9:A126.Search in Google Scholar
20. Hackam DG. Cardiovascular risk prevention in peripheral arterial disease. J Vasc Surg 2005; 41:1070–3.10.1016/j.jvs.2005.03.009Search in Google Scholar PubMed
21. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381–6.10.1056/NEJM199202063260605Search in Google Scholar PubMed
22. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004; 6:365–8.10.1016/j.ejheart.2004.01.011Search in Google Scholar PubMed
23. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29:439–93.Search in Google Scholar
24. Vainas T, Stassen FR, de Graaf R, Twiss EL, Herngreen SB, Welten RJ, et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg 2005; 42:243–51.10.1016/j.jvs.2005.03.060Search in Google Scholar PubMed
25. Svensson P, de Faire U, Niklasson U, Hansson LO, Ostergren J. Plasma NT-proBNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood Press 2005; 14:99–106.10.1080/08037050510008931Search in Google Scholar
26. Diehm C, Kareem S, Lawall H. Epidemiology of peripheral arterial disease. Vasa 2004; 33:183–9.10.1024/0301-1526.33.4.183Search in Google Scholar
27. Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW Jr. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005; 41:816–22.10.1016/j.jvs.2005.01.047Search in Google Scholar
28. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993; 88:837–45.10.1161/01.CIR.88.3.837Search in Google Scholar
29. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J 1996; 313:1440–4.10.1136/bmj.313.7070.1440Search in Google Scholar
30. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999; 19:538–45.10.1161/01.ATV.19.3.538Search in Google Scholar
31. Park H, Das M, Aronow WS, McClung JA, Belkin RN. Relation of decreased ankle-brachial index to prevalence of atherosclerotic risk factors, coronary artery disease, aortic valve calcium, and mitral annular calcium. Am J Cardiol 2005; 95:1005–6.10.1016/j.amjcard.2004.12.050Search in Google Scholar
32. Kelly R, Staines A, MacWalter R, Stonebridge P, Tunstall-Pedoe H, Struthers AD. The prevalence of treatable left ventricular systolic dysfunction in patients who present with non cardiac vascular episodes: a case control study. J Am Coll Cardiol 2002; 39:219–24.10.1016/S0735-1097(01)01725-9Search in Google Scholar
33. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995; 92:1558–64.10.1161/01.CIR.92.6.1558Search in Google Scholar PubMed
34. Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 2005; 128:21–9.10.1378/chest.128.1.21Search in Google Scholar PubMed
35. Arat-Ozkan A, Kaya A, Yigit Z, Balci H, Okcun B, Yazicioglu N, et al. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography 2005; 22:473–8.10.1111/j.1540-8175.2005.04085.xSearch in Google Scholar
36. Kikuta K, Yasue H, Yoshimura M, Morita E, Sumida H, Kato H, et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J 1996; 132:101–7.10.1016/S0002-8703(96)90396-8Search in Google Scholar
37. Aslan D, Apple FS. Ischemia modified albumin: clinical and analytical update. Lab Med 2004; 35:1–5.10.1309/XXYETJN8YM9HBD9CSearch in Google Scholar
38. Troxler M, Thompson D, Homer-Vanniasinkam S. Ischaemic skeletal muscle increases serum ischaemia modified albumin. Eur J Vasc Endovasc Surg 2005. In press (doi:10.1016/j.ejvs.2005.06.019).Search in Google Scholar
39. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski, JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003; 107:2403–5.10.1161/01.CIR.0000072764.18315.6BSearch in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
Articles in the same Issue
- Allergy testing: the role of recombinant allergens
- Autoimmune diagnostics in diabetes mellitus
- Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis
- Autoimmune bullous disorders
- Laboratory network of excellence: enhancing patient safety and service effectiveness
- Novel mutations in the 5′-UTR of the FOLR1 gene
- CYP2C8 polymorphism among the Portuguese
- Actual levels of soy phytoestrogens in children correlate with thyroid laboratory parameters
- Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer
- Comparison of Brucella immunoglobulin M and G flow assays with serum agglutination and 2-mercaptoethanol tests in the diagnosis of brucellosis
- Experimental and computer modelling speciation studies of the effect of pH and phosphate on the precipitation of calcium and magnesium salts in urine
- Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies
- Establishment of an indocyanine green test using an automatic chemistry analyzer
- Relationship between serum sialic acids, sialic acid-rich inflammation-sensitive proteins and cell damage in patients with acute myocardial infarction
- Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease
- Nitration of human plasminogen by RAW 264.7 macrophages reduces streptokinase-induced plasmin activity
- Comparison of triglyceride concentration with lipemic index in disorders of triglyceride and glycerol metabolism
- Measurement of glycated hemoglobin (HbA1c) with an automated POCT instrument in comparison with HPLC and automated immunochemistry method: evaluation of the influence of hemoglobin variants
- Analytical performance and clinical efficacy for cardiovascular risk estimation of an Olympus immunoturbidimetric high-sensitivity C-reactive protein assay
- Systemic matrix metalloproteinase-9 (MMP-9) levels as prognostic indexes of bone disease in patients with multiple myeloma
- Systemic levels of matrix metalloproteinase-9 in patients with multiple myeloma may be useful as a prognostic index of bone disease. Reply to the Letter by Demacq and Montenegro
- Society of Medical Biochemists of Serbia and Montenegro: 50-year anniversary
Articles in the same Issue
- Allergy testing: the role of recombinant allergens
- Autoimmune diagnostics in diabetes mellitus
- Diagnosis and prognosis of early rheumatoid arthritis, with special emphasis on laboratory analysis
- Autoimmune bullous disorders
- Laboratory network of excellence: enhancing patient safety and service effectiveness
- Novel mutations in the 5′-UTR of the FOLR1 gene
- CYP2C8 polymorphism among the Portuguese
- Actual levels of soy phytoestrogens in children correlate with thyroid laboratory parameters
- Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer
- Comparison of Brucella immunoglobulin M and G flow assays with serum agglutination and 2-mercaptoethanol tests in the diagnosis of brucellosis
- Experimental and computer modelling speciation studies of the effect of pH and phosphate on the precipitation of calcium and magnesium salts in urine
- Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies
- Establishment of an indocyanine green test using an automatic chemistry analyzer
- Relationship between serum sialic acids, sialic acid-rich inflammation-sensitive proteins and cell damage in patients with acute myocardial infarction
- Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease
- Nitration of human plasminogen by RAW 264.7 macrophages reduces streptokinase-induced plasmin activity
- Comparison of triglyceride concentration with lipemic index in disorders of triglyceride and glycerol metabolism
- Measurement of glycated hemoglobin (HbA1c) with an automated POCT instrument in comparison with HPLC and automated immunochemistry method: evaluation of the influence of hemoglobin variants
- Analytical performance and clinical efficacy for cardiovascular risk estimation of an Olympus immunoturbidimetric high-sensitivity C-reactive protein assay
- Systemic matrix metalloproteinase-9 (MMP-9) levels as prognostic indexes of bone disease in patients with multiple myeloma
- Systemic levels of matrix metalloproteinase-9 in patients with multiple myeloma may be useful as a prognostic index of bone disease. Reply to the Letter by Demacq and Montenegro
- Society of Medical Biochemists of Serbia and Montenegro: 50-year anniversary
